Usern_member

Prashant Kesharwani

USERN Advisory Board

In brief, I would like to apprise you that at the young age of 38, I have published more than 300 articles and 20 international books as an Editor (Elsevier). My cumulative impact factor is approximately 1986.217, total citations are 15041, h-index-64 and i-10 index is 237 [https://scholar.google.co.in/citations?user=DJkvOAQAAAAJ&hl=en]. I have 11 international publications published in very high impact factor journals (2 in Progress in Polymer Sciences IF 31.063, 4 in Molecular Sciences IF 41.444, 1 in Progress in Material Sciences IF 48.580, 2 in Drug Resistance Update IF 22.841 and 2 in Material Todays IF 32.072).



I have been listed in the “WORLD’S TOP 2% SCIENTISTS” list 2020, 2021 and 2022 in the field of “Pharmacology & Pharmacy” published by Stanford University.



I have also received 6 research grants from various funding bodies [ICMR (4), SERB-DST (1) & UGC (1)] & having more than 300 international publications including 18 international books (as an Editor). I am the only candidate who has joined Jamia Hamdard with 5 advanced salary increments. From best of my knowledge, I am the only candidate from pharmaceutical background who has been awarded the most Prestigious "Ramanujan Fellowship (SERB-DST). I have academic (India and Malaysia), research (India and USA) and industrial experience at international level.




PROFESSIONAL RECOGNITION, AWARDS, FELLOWSHIPS RECEIVED:



   1.  Listed in the “WORLD’S TOP 2% SCIENTISTS” list 2022 in the field of “Pharmacology & Pharmacy” published by Stanford University


   2.  Listed in the “WORLD’S TOP 2% SCIENTISTS” list 2021 in the field of “Pharmacology & Pharmacy” published by Stanford University


   3.  Third position on poster presentation in the Graduate and Postdoctoral Research Symposium (23 March 2016) at Wayne State University, Graduate school, Detroit, MI, USA (INTERNATIONAL).


   4.  Awarded most prestigious “SERB-RAMANUJAN FELLOWSHIP”.


   5.  I am the only candidate who has joined Jamia Hamdard with 5 advanced salary increments.


   6.  Young Innovator Award (Gold medal) in 1st International Conferences on Innovative Pharmacy & Pharmaceutical Sciences 2012 (ICIPPS-2012).


   7.  Awarded first position on oral presentation in the DST & DBT sponsored national seminar on “Nanobiotechnology” (2013) at Guru Ramdas Khalsa, Institute of Science & Technology, (M.P.).


   8.  Awarded “Excellence Research Award” (2014) second position in the MPCST sponsored national seminar at Adina Institute of Pharmaceutical Sciences, Sagar (M.P.)


   9.  Awarded “fellowship for training of Young Scientist” (2014-15) of M.P. Council of Science and Technology at the 29th M.P. Young Scientist Congress.


 10. Awarded twice “fellowship for training of Young Scientist” (2013-14) of M.P. Council of Science and Technology at the 28th M.P. Young Scientist Congress.


 11. International Travel Award from DST (New Delhi) 2012


 12. International Travel Grant from INSA (CCSTDS, Chennai) 2012


 13. International Travel Award/Grant from CSIR (New Delhi) 2018.


 14. Awarded ICMR-SRF fellowship for pursuing PhD 2012.


 15. Awarded AICTE-JRF fellowship for pursuing M. Pharma 2007.




EDUCATION:


PhD, Pharmaceutics, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar (M.P.), India 2014.


M. Pharma., Pharmaceutics, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar (M.P.), India 2009.


B. Pharma., Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Dr. H. S. Gour Central University, Sagar (M.P.), India 2007.



PROFESSIONAL EXPERIENCE:


December 2018-Till date          
Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed to be University), New Delhi, INDIA-110062


April 2017-December 2018        SERB Ramanujan Fellow, CSIR-Central Drug Research Institute (CDRI), Lucknow, 226031, U.P., India


September 2016- April 2017      Lecturer, School of Pharmacy, Department of Pharmaceutical Technology, International Medical University (IMU), Kuala Lumpur, Malaysia


September 2014-July 2016         Postdoctoral Fellow,
Department of Pharm. Sciences, Eugene Applebaum College of Pharmacy and Health Sciences; Wayne State University, Detroit (MI) USA


January 2012-August 2014     ICMR-SRF,
Dr. Hari Singh Gour Central University, Sagar (M.P.), India


October 2010-January 2012       Guest faculty, Dr. Hari Singh Gour Central University, Sagar (M.P.), India


January 2010-July 2010         
Management Trainee, Indoco Remedies Ltd. Navi Mumbai, India


June 2007-August 2007         
Lecturer, Adina Institute of Pharmaceutical Sciences, Sagar M.P



RESEARCH GRANT:


1. ICMR Extramural project]: [Jamia Hamdard, New Delhi]


PI: Dr Prashant Kesharwani                                     
Duration: April 2019-March 2022


Title: Survivin siRNA targeted poly(propylene imine) dendrimer loaded with doxorubicin and lycopene against triple negative breast cancer


Budget: 37 Lac


2. [SERB Ramanujan fellowship]: [CSIR-CDRI Lucknow & Jamia Hamdard, New Delhi]


PI: Dr Prashant Kesharwani                                     
Duration: April 2017- March 2020


Title: Aptamer anchored smart multifunctional dendrimer-BSA nanoarchitectures for the effective treatment of drug resistant non-small cell lung cancer


Budget: 53.40 Lac



3. [UGC start up grant]: [Jamia Hamdard, New Delhi]


PI: Dr Prashant Kesharwani              
                 Duration: September 2019- August 2021


Title: RGD-engineered poly (propylene imine) dendrimers conjugated to iron oxide nanoparticles for targeted tumor magnetic resonance imaging (MRI)


Budget: 10 Lac



4. [ICMR Extramural project]: [Jamia Hamdard, New Delhi]


PI: Dr Prashant Kesharwani                          
    Duration: April 2020-March 2023


Title: Aptamer engineered smart multifunctional dendrimer-BSA nano-architectures targeting stem cell marker CD133 for triple-negative breast cancer therapy


Budget: 35 Lac



5. [ICMR Extramural project]: [Jamia Hamdard, New Delhi]


PI: Dr Prashant Kesharwani                          
    Duration: March 2022-February 2025


Title: Cell death inducing targeted therapy enhanced by amphiphilic co-block polymeric nanoscale drug delivery tool for triple-negative breast cancer therapy


Budget: 37 Lac



6. [ICMR Extramural project]: [Jamia Hamdard, New Delhi]


PI: Dr Prashant Kesharwani                          
    Duration: March 2022-February 2025


Title: Strategic viral-mimicking, DNA-ejecting polyplex as a novel nanotherapeutic tool for breast cancer therapy


Budget: 35.18 Lac



PUBLICATION DETAILS:


Year 2010:



  1. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let's meet the challenge. Int J Pharm. 2010;394(1-2):122-42.
    (Impact factor 5.875)
  2. Kothule KU, Kesharwani P, Gidwani SK. Synthesis and biological evaluation of some schiffs bases of 2-substituted- 1, 3, 4-Oxadiazole. Asian J Res Chem. March 2010;3(4):1-3.
  3. Kothule KU, Kesharwani P, Gidwani SK, Gide P. Development and characterization of chitosan nanoparticles and improvement of oral bioavailability of poorly water soluble acyclovir. Research J. Pharm. and Tech. Oct 2010;3(4): 1-5.

Year 2011:



  1. Kesharwani P, Tekade RK, Gajbhiye V, Jain K, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7(3):295-304.
    (Impact factor 6.692)
  2. Kesharwani P, Jain K, Tekade RK, Gajbhiye V, Jain NK. Spectrophotometric estimation of paclitaxel. Int J Adv Pharm Sci 2011;2:29-32.
  3. Kesharwani P, Gajbhiye V, Tekade RK, Jain NK. Evaluation of dendrimer safety and efficacy through cell line studies. Curr Drug Targets. 2011;12(10):1478-97.
    (Impact factor 4.27)

Year 2012:



  1. Dubey M, Kesharwani P, Tiwari A, Chandel R, Raja K, Sivakumar T. Formulation and evaluation of floating microsphere containing anti diabetic drug. Int. J. Pharm. Chem Sci. 2012;1:1038-47.
  2. Kesharwani P, Gajbhiye V, Jain NK. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials. Oct 2012;33(29):7138-50.
    (Impact factor 12.479)
  3. Kesharwani P, Ghanghoria R, Jain NK. Carbon nanotube exploration in cancer cell lines. Drug Discov Today. 2012;17(17-18):1023-30.
    (Impact factor 7.851)
  4. Jain K, Kesharwani P, Gupta U, Jain NK. A review of glycosylated carriers for drug delivery. Biomaterials. 2012;33(16):4166-86.
    (Impact factor 12.497)

Year 2013:



  1. Thakur S, Kesharwani P, Tekade RK, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor targeting potential of folate modified PPI dendrimers. J Nanopart Res. April 2013;15:1625.
    (Impact factor 2.278)
  2. Ghanghoria R, Kesharwani P, Agashe HB, Jain NK. Transdermal delivery of cyclodextrin-solubilized curcumin. Drug Deliv. and Transl. Res. June 2013;3:272-85.
    (Impact factor 4.617)
  3. Jain A, Jain K, Kesharwani P, Jain NK. Low density lipoproteins mediated nanoplatforms for cancer targeting. J Nanopart Res (2013) 15:1888.
    (Impact factor 2.278)

Year 2014:



  1. Kesharwani P, Tekade RK, Jain NK. Generation dependent cancer targeting potential of poly(propyleneimine) dendrimer. Biomaterials. July 2014;35(21):5539-48.
    (Impact factor 12.479)
  2. Kesharwani P, Tekade RK, Jain NK. Formulation development and in vitro-in vivo assessment of the fourth-generation PPI dendrimer as a cancer-targeting vector. Nanomedicine (Lond). Feb 2014;9(15):2291-308.
    (Impact factor 5.824)
  3. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci, Feb 2014;39:268-307.
    (IMPACT FACTOR 29.190)
  4. Mishra V, Kesharwani P, Jain NK. siRNA nanotherapeutics: a Trojan horse approach against HIV. Drug Discov Today. Dec 2014;19(12):1913-20.
    (Impact factor 7.851)

Year 2015:



  1. Kesharwani P, Tekade RK, Jain NK. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm Res. April 2015;32(4):1438-50.
    (Impact factor 4.200)
  2. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Parenterally administrable nano-micelles of Difluorobenzylidene curcumin difluorinated for treating pancreatic cancers. Colloids Surf. B Biointerfaces, Aug 2015;132:138–45. (Impact factor 5.268)
  3. Kesharwani P, Xie L, Maob G, Padhye S, Iyer AK. Hyaluronic acid-conjugated polyamidoamine dendrimers for CD44 target mediated 3,4-difluorobenzylidene curcumin delivery for treating pancreatic cancer. Colloids Surf. B Biointerfaces, Dec 2015;136:413-23. (Impact factor 5.268)
  4. Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic acid engineered nano-micelles loaded with 3, 4-difluorobenzylidene curcumin for targeted killing of CD44+ stem-like pancreatic cancer cells. Biomacromolecules, Aug 2015;16:3042–53. (Impact factor 6.988)
  5. Kesharwani P, Mishra V, Jain NK. Generation dependent hemolytic profile of folate engineered poly(propyleneimine) dendrimer. J. Drug Deliv. Sci. & Tech. Aug 2015;28:1-6.
    (Impact factor 3.981)
  6. Amjad MW, Mohd Amin MCI, Katas H, Butt AM, Kesharwani P, Iyer AK. The in vivo anti-tumor activity of folate-conjugated cholic acid-polyethylenimine micelles for the co-delivery of doxorubicin and siRNA to colorectal adenocarcinomas. Molecular Pharmaceutics Dec 2015;12(12):4247-58. (Impact factor 4.939)
  7. Mansuri S, Kesharwani P, Tekade RK, Jain NK. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. European Journal of Pharmaceutics and Biopharmaceutics, Volume 102, May 2016, Pages 202-213 (Impact factor 5.571)
  8. Singh R, Kesharwani P, Mehra NK, Singh S, Banerjee S, Jain N.K. Development and characterization of Saquinavir entrapped Poly (D, L-Lactide-co-Glycolide) (PLGA) nanoparticles for anti-tumor activity. Drug Dev Ind Pharm. March 2015;41(11):1888-901. (Impact factor 3.232)
  9. Tiwari A, Kesharwani P*, Gajbhiye V, Jain NK. Synthesis and characterization of dendro-PLGA nanoconjugate for protein stabilization. Colloids Surf. B Biointerfaces, Oct 2015;134:279-86.
    (Impact factor 5.268)
  10. Birdhariya B, Kesharwani P, Jain NK. Effect of surface capping on targeting potential of folate decorated poly (propylene imine) dendrimers. Drug Dev Ind Pharm. Aug 2015;41(8):1393-9.
    (Impact factor 3.232)
  11. Jain S, Kesharwani P, Tekade RK, Jain NK. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Dev Ind Pharm. March 2015;41(5):722-7.
    (Impact factor 3.232)
  12. Kesharwani P, Iyer AK, Banerjee S, Gupta U, MCI Mohd Amin, Sarkar FH, Padhye S. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Material Today, Dec 2015;18:565–72.
    (IMPACT FACTOR: 32.072)
  13. Kesharwani P*, Mishra V, Jain NK. Validation of carbon nanotubes based nano-therapeutics through cell line testing. Drug Discovery Today, Sep 2015;20:1049-60.
    (Impact factor 7.851)
  14. Kesharwani P, Tekade RK, Jain NK. Dendrimer generational nomenclature: the need to harmonize. Drug Discov Today, May 2015;20(5):497-9.
    (Impact factor 7.851)
  15. Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery. Drug Discov Today, May 2015;20(5):536-547.
    (Impact factor 7.851)
  16. Gothwal A, Kesharwani P*, Gupta U, Khan I, Mohd Amin MCI, Banerjee S, Iyer AK. Dendrimers as an effective nanocarrier in cardiovascular disease. Current Pharm. Design 2015;21:4519-26.
    (Impact factor 3.288)
  17. Jain A, Kesharwani P*, Garg NK, Jain A, Nirbhavane P, Banerjee S, Mohd Amin MCI, Iyer AK. Nano-constructed carriers loaded with antioxidant: Boon for cardiovascular system. Current Pharm. Design. 2015;21:4456-64.
    (Impact factor 3.288)
  18. Thakur S, Kesharwani P*, Tekade RK, Jain NK. Impact of pegylation on biopharmaceutical properties of dendrimers. Polymer, Feb 2015;59:67-92.
    (Impact factor 4.430)

Year 2016:



  1. Ng KE, Amin MC, Katas H, Amjad MW, Butt AM, Kesharwani P, Iyer AK. pH-responsive triblock copolymeric micelles decorated with a cell-penetrating peptide provide efficient doxorubicin delivery. Nanoscale Res Lett. Dec 2016;11(1):539. (Impact factor 2.833)
  2. Ghanghoria R, Kesharwani P, Tekade RK, Jain NK. Targeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers. Journal of Controlled Release, Volume 269, 10 January 2018, Pages 277-301 (Impact factor 9.776)
  3. Kesharwani P,1,* Jain A, Jain A, Jain AK, Garg NK, Tekade RK, Singh TRR, Iyer AK. Cationic bovine serum albumin (CBA) conjugated poly lactic-co-glycolic acid (PLGA) nanoparticles for extended delivery of methotrexate into brain tumors. RSC Adv. Aug 2016;6:89040-50.
    (Impact factor 3.361)
  4. Nag M, Gajbhiye V, Kesharwani P, Jain NK. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. Colloids Surf B Biointerfaces. Dec 2016;148:363-370.
    (Impact factor 5.268)
  5. Mahor A, Prajapati SK, Verma A, Gupta R, Iyer AK,
    Kesharwani P    *. Moxifloxacin loaded gelatin nanoparticles for ocular delivery: Formulation and in-vitro, in-vivo evaluation. J Colloid Interface Sci. Dec 2016;483:132-8.
    (Impact factor 8.128)
  6. Patel HK, Gajbhiye V, Kesharwani P, Jain NK. Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. J Colloid Interface Sci. Nov 2016;482:142-50.
    (Impact factor 8.128)
  7. Mahor A, Prajapati SK, Verma A, Gupta R, Singh TRR,
    Kesharwani P    *. Development, in-vitro and in-vivo characterization of gelatin nanoparticles for delivery of an anti-inflammatory drug. Journal of Drug Delivery Science and Technology Dec 2016;36:55–61.
    (Impact factor 3.981)
  8. Luong D, Kesharwani P, Killinger BA, Moszczynska A, Sarkar FH, Padhye S, Rishi AK, Iyer AK. Solubility enhancement and targeted delivery of a potent anticancer flavonoid analogue to cancer cells using ligand decorated dendrimer nano-architectures. J Colloid Interface Sci. Dec2016;484:33-43.
    (Impact factor 8.128)
  9. Deshmukh R, Sharma L, Tekade M, Kesharwani P, Trivedi P, Tekade RK. Force degradation behavior of glucocorticoid deflazacort by UPLC: isolation, identification and characterization of degradant by FTIR, NMR and mass analysis. J Biomed Res. March 2016;30(2):149–61.
  10. Choudhary S, Jain A, Mohd Amin MCI, Mishra V, Agrawal GP,
    Kesharwani P    *. Stomach specific polymeric low density microballoons as a vector for extended delivery of rabeprazole and amoxicillin for treatment of peptic ulcer. Colloids and Surfaces B: Biointerfaces. March 2016;141:268-277.
    (Impact factor 5.268)
  11. Jain A, Garg, NK, Jain A, Jain AK, Nirbhavane P, Tyagi RK,
    Kesharwani P. Synergistic approach of Adapalene-Loaded Nanostructured lipid carriers, vitamin C Co-adminstration for Treating Acne. Drug Dev Ind Pharm. Nov 2016;42(6):897-905.
    (Impact factor 3.232)
  12. Butt AM, Amin MCIM, Katas H, Murad A, Azian N, Rahman J,
    Kesharwani P    . Doxorubicin and siRNA co-delivery via chitosan-coated pH-responsive mixed micellar polyplexes for enhanced cancer therapy in multidrug-resistant tumors. Mol. Pharmaceutics Oct 2016, 13, 12, 4179–4190
    (Impact factor 4.939)
  13. Soni N, Soni N, Pandey H, Maheshwari R, Kesharwani P, Tekade RK. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci. Nov 2016;481:107-16.
    (Impact factor 9.965)
  14. Sharma AK, Gothwal A, Kesharwani P, Alsaab H, Iyer AK, Gupta U. Dendrimer nanoarchitectures for cancer diagnosis and anticancer drug delivery. Drug Discov Today. 2016 doi: 10.1016/j.drudis.2016.09.013.
    Drug Discov Today. 2017 Feb;22(2):314-326. doi: 10.1016/j.drudis.2016.09.013.
    (Impact factor 7.851).
  15. Luong D1, Kesharwani P1, Deshmukh R, Mohd Amin MC, Gupta U, Greish K, Iyer AK. PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Acta Biomater. Oct 2016;43:14-29. (Impact factor 8.947)
  16. Tekade RK, Tekade M, Kesharwani P, D'Emanuele A. RNAi-combined nano-chemotherapeutics to tackle resistant tumors. Drug Discovery Today, Volume 21, Issue 11, November 2016, Pages 1761-1774. doi: 10.1016/j.drudis.2016.06.029.
    (Impact factor 7.851)
  17. Kaur D, Jain K, Mehra, NK, Kesharwani P, Jain NK. A review on comparative study of PPI and PAMAM dendrimers. J Nanopart Res. June 2016:18: 146. doi:10.1007/s11051-016-3423-0.
    (Impact factor 2.278)
  18. Shukla A, Mishra V, Kesharwani P*. Bilosomes in context to oral immunization: need of rigorous exploitation. Drug Discov Today. June 2016;21:888-99.
    (Impact factor 7.851)
  19. Kesharwani P, Ghanghoria R, Jain NK. Experimental models for evaluation of nanoparticles in cancer therapy. Mini Rev Med Chem. 2017;17(18):1725-1745.
    (Impact factor 3.862)
  20. Ghanghoria R, Kesharwani P, Jain NK. Significance of various experimental models and assay techniques in cancer diagnosis. Mini Rev Med Chem. 2017;17(18):1713-1724
    (Impact factor 3.862)
  21. Mishra V1, Kesharwani P1,*. Dendrimer technologies for brain tumor. Drug Discov Today. May 2016;21(5):766-78.
    (Impact factor 7.851)
  22. Mansuri S, Kesharwani P, Jain K, Jain NK. Mucoadhesion: A promising approach in drug delivery system. Reactive and Functional Polymers 2016;100:151–72.
    (Impact factor 3.975)
  23. Khan I, Gothwal A, Sharma AK, Kesharwani P, Gupta L, Iyer AK, Gupta U. PLGA nanoparticles and their versatile role in anticancer drug delivery. Crit Rev Ther Drug Carrier Syst. 2016;33(2):159-93.
    (Impact factor 5.367)
  24. Dwivedi N, Shah J, Mishra V, Mohd Amin MCI, Iyer AK,
    Kesharwani P    *. Dendrimer mediated approaches for the treatment of brain tumor. J Biomater Sci Polym Ed. Feb 2016;27(7):557-80
    (Impact Factor 3.517).

Year 2017:



  1. Kesharwani P*, Gorain B, Low SY, Tan SA, Ling ECS, Lim YK, Chin CM, Lee PY, Lee CM, Ooi CH, Choudhury H, Pandey M. Nanotechnology based approaches for anti-diabetic drugs delivery. Diabetes Res Clin Pract. Feb 2018;136:52-77. (Impact factor 5.602)
  2. Khurana RK, Beg S, Burrow AJ, Vashishta RK, Katare OP, Kaur S,
    Kesharwani P, Singh KK, Singh B. Enhancing biopharmaceutical performance of an anticancer drug by long chain PUFA based self-nanoemulsifying lipidic nanomicellar systems. Eur J Pharm Biopharm. 2017 Dec;121:42-60. (Impact factor 5.571)
  3. Cheriyan VT, Alsaab HO, Sekhar S, Stieber C, Kesharwani P, Sau S, Muthu M, Polin LA, Levi E, Iyer AK, Rishi AK. A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma. Oncotarget. Sep 2017;8:104928-104945.
    (Impact factor 5.168)
  4. Jain A, Sharma G, Kushwah V, Garg NK, Kesharwani P, Ghoshal G, Singh B, Shivhare US, Jain S, Katare OP. Methotrexate and beta-carotene loaded-lipid polymer hybrid nanoparticles: a preclinical study for breast cancer. Nanomedicine (Lond). 2017 Aug;12(15):1851-1872. doi: 10.2217/nnm-2017-0011. Epub 2017 Jul 13.
    (Impact factor 5.307)
  5. Luong D, Sau S, Kesharwani P, Iyer AK. Polyvalent folate-dendrimer-coated iron oxide theranostic nanoparticles for simultaneous magnetic resonance imaging and precise cancer cell targeting. Biomacromolecules. April 2017;18(4):1197-1209.
    (Impact factor 6.998)
  6. Shringirishi M, Mahor A, Gupta R, Prajapati SK, Bansal K,
    Kesharwani P*. Fabrication and characterization of nifedipine loaded β-cyclodextrin nanosponges: An in vitro and in vivo evaluation. Journal of Drug Delivery Science and Technology. 2017;41:344-350.
    (Impact factor 3.981)
  7. Madheswaran T, Baskaran R, Yoo BK, Kesharwani P*. In vitro and in vivo skin distribution of 5α-reductase inhibitors loaded into liquid crystalline nanoparticles. J Pharm Sci. 2017 Nov;106(11):3385-3394. doi: 10.1016/j.xphs.2017.06.016
    (Impact factor 3.534)
  8. Luong D1, Kesharwani P1, Alsaab HO, Sau S, Padhye S, Sarkar FH, Iyer AK. Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers. Colloids Surf B Biointerfaces. Sep 2017;157:490-502. (Impact factor 5.268)
  9. Gawde KA, Kesharwani P, Sau S, Sarkar FH, Padhye S, Kashaw SK, Iyer AK. Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue. J Colloid Interface Sci. June 2017;496:290-299. (Impact factor 8.128)
  10. Alsaab H, Alzhrani RM, Kesharwani P, Sau S, Boddu SH, Iyer AK. Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma. Pharmaceutics. 2017 Apr 18;9(2). pii: E15. doi: 10.3390/pharmaceutics9020015.
    (Impact factor 6.321)
  11. Amjad MW1, Kesharwani P1, Mohd Amin MCI, Iyer AK. Recent advances in the design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA in cancer therapy. Progress in Polymer Science, January 2017;64:154–81. (IMPACT FACTOR 29.190)
  12. Wickens JM, Alsaab HO, Kesharwani P, Bhise K, Amin MCIM, Tekade RK, Gupta U, Iyer AK. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. Drug Discov Today. April 2017;22:665-680.
    (Impact factor 7.851)
  13. Choudhury H, Gorain B, Pandey M, Chatterjee LA, Sengupta P, Das A, Molugulu N,
    Kesharwani P*. Recent update on nanoemulgel as topical drug delivery system. J Pharm Sci. 2017 Jul;106(7):1736-1751.
    (Impact factor 3.534)
  14. Gupta U, Kumar H, Mishra G, Kumar Sharma A, Gothwal A,
    Kesharwani P    . Intranasal drug delivery: a non-invasive approach for the better delivery of neurotherapeutics. Pharm Nanotechnol. 2017;5(3):203-214. doi: 10.2174/2211738505666170515113936.
  15. Md S, Haque S, Madheswaran T, Zeeshan F, Meka VS, Radhakrishnan AK,
    Kesharwani P*. Lipid based nanocarriers system for topical delivery of photosensitizers. Drug Discovery Today, Volume 22, Issue 8, August 2017, Pages 1274-1283. doi: 10.1016/j.drudis.2017.04.010
    (Impact factor 7.851)
  16. Soni N, Tekade M, Kesharwani P, Bhattacharya P, Maheshwari R, Dua K, Hansbro PM, Tekade RK. Recent advances in oncological submissions of dendrimer. Curr Pharm Des. Aug 2017. doi: 10.2174/1381612823666170329150201. [Epub ahead of print]. (Impact factor 3.116)
  17. Gorain B, Tekade M, Kesharwani P, Iyer AK, Kalia K, Tekade RK. The use of nanoscaffolds and dendrimers in tissue engineering. Drug Discov Today. 2017 Apr;22(4):652-664. doi: 10.1016/j.drudis.2016.12.007. Epub 2017 Feb 20. (Impact factor 7.851)
  18. Meka VS, Sing MKG, Pichika MR, Nali SR, Kolapalli VRM,
    Prashant Kesharwani*    . A comprehensive review on polyelectrolyte complexes. Drug Discovery Today, Volume 22, Issue 11, November 2017, Pages 1697-1706. DOI 10.1016/j.drudis.2017.06.008
    (Impact factor 7.851)
  19. Kesharwani P*, Gothwal A, Iyer AK, Jain K, Chourasia MK, Gupta U. Dendrimer nanohybrid carrier systems: An expanding horizon for targeted drug and gene delivery. Drug Discovery Today, Volume 23, Issue 2, February 2018, Pages 300-314 (Impact factor
    7.851)
  20. Hussain Z, Thu HE, Shuid AN, Kesharwani P, Khan S, Hussain F. Phytotherapeutic potential of natural herbal medicines for the treatment of mild-to-severe atopic dermatitis: A review of human clinical studies. Biomedicine & Pharmacotherapy, Sep 2017;93:596–608. (Impact factor 6.529)
  21. Tatiparti K, Gawde KA, Alasab H, Sau S, Kashaw SK, Kesharwani P, Iyer AK. Pancreatic Cancer - The Role of Hypoxia. Journal of Pancreatic Cancer and Treatment, 2017, 1(1):1-5.
  22. Choudhury H, Pandey M, Hua CK, Mun CS, Jing JK, Kong L, Ern LY, Ashraf NA, Kit SW, Yee TS, Pichika MR, Gorain B,
    Kesharwani P*. An update on natural compounds in the remedy of diabetes mellitus: A systematic review. Journal of Traditional and Complementary Medicine, Volume 8, Issue 3, July 2018, Pages 361-376. DOI https://doi.org/10.1016/j.jtcme.2017.08.012(Impact factor 4.221)
  23. Jain A, Jain A, Parajuli P, Mishra V, Ghoshal G, Singh B, Shivhare US, Katare OP,
    Kesharwani P*. Recent advances in galactose-engineered nanocarriers for the site-specific delivery of siRNA and anticancer drugs. Drug Discovery Today, Volume 23, Issue 5, May 2018, Pages 960-973 (Impact factor 7.851)
  24. Thanikachalam PV, Ramamurthy S, Wong ZW, Koo BJ, Wong JY, Abdullah MF, Chin YH, Chia CH, Tan JY, Neo WT, Tan BS, Khan WF,
    Kesharwani P*. Current attempts to implement microRNA-based diagnostics and therapy in cardiovascular and metabolic disease: a promising future. Drug Discovery Today, Volume 23, Issue 3, March 2018, Pages 460-480 (Impact factor 7.851)
  25. Md S, Bhattmisra SK, Zeeshan F, Shahza N, Mujtaba MA, Meka VS, Radhakrishnan A,
    Kesharwani P, Baboot S, Ali J. Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. Journal of Drug Delivery Science and Technology. Feb 2018;43:295-310. (Impact factor 3.981)
  26. Molugulu N, Yee LS, Ye YT, Khee TC, Nie LZ, Yee NJ, Yee TK, Liang TC,
    Kesharwani P*. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract. Oct 2017;132:157-168. (Impact factor 5.602)
  27. Choudhury H, Gorain B, Pandey M, Kumbhar SA, Tekade RK, Iyer AK,
    Kesharwani P*. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int J Pharm. Aug 2017;529(1-2):506-522.
    (Impact factor 5.875)
  28. Khan I, Kumar H, Mishra G, Gothwal A, Kesharwani P, Gupta U. Polymeric nanocarriers: A new horizon for the effective management of breast cancer. Curr Pharm Des. Volume 23 , Issue 35 , 2017, Page: [5315 - 5326], DOI: 10.2174/1381612823666170829164828
    (Impact factor 3.116)

Year 2018:



  1. Khurana RK, Jain A, Jain A, Sharma T, Singh B, Kesharwani P*. Administration of antioxidants in cancer: debate of the decade. Drug Discovery Today, Volume 23, Issue 4, April 2018, Pages 763-770 DOI https://doi.org/10.1016/j.drudis.2018.01.021(Impact factor
    7.851)
  2. Mishra V, Patil A, Thakur S,Kesharwani P*. Carbon dots: emerging theranostic nanoarchitectures. Drug Discov Today. Volume 23, Issue 6, June 2018, Pages 1219-1232
    (Impact factor 7.851)
  3. Khurana RK, Kumar R, Gaspar BL, Welsby G, Welsby P,
    Kesharwani P, Katare OP, Singh KK, Singh B. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model. Materials Science and Engineering: C, Volume 91, 1 October 2018, Pages 645-658. https://doi.org/10.1016/j.msec.2018.05.010
    (Impact factor 7.328)
  4. Jain A, Sharma G, Ghoshal G, Kesharwani P, Singh B, Shivhare US, Katare OP. Lycopene loaded whey protein isolate nanoparticles: An innovative endeavor for enhanced bioavailability of lycopene and anti-cancer activity. International Journal of Pharmaceutics, Volume 546, Issues 1–2, 30 July 2018, Pages 97-105. https://doi.org/10.1016/j.msec.2018.05.010
    (Impact factor 5.875)
  5. Bapat RA, Chaubal TV, Joshi CP, Bapat PR, Choudhury H, Pandey M, Gorain B,
    Kesharwani P*. An overview of application of silver nanoparticles for biomaterials in dentistry. Materials Science and Engineering: C, Volume 91, 1 October 2018, Pages 881-898 DOI:
    https://doi.org/10.1016/j.msec.2018.05.069(Impact factor 7.328)
  6. Pandey M, Choudhury H, Yi CX, Mun CW, Ping GK, Rou GX, Singh BJKAAJ, Jhee ANA, Chin LK,
    Kesharwani P, Gorain B, Hussain Z. Recent updates on novel approaches in insulin drug delivery: A review of challenges and pharmaceutical implications. Curr Drug Targets. 2018 May 22. doi: 10.2174/1389450119666180523092100. [Epub ahead of print] (Impact factor 3.465)
  7. Singh G, Kesharwani P*, Srivastava AK. Tuberculosis Treated by Multiple Drugs: An Overview. Curr Drug Deliv. 2018;15(3):312-320.
    (Impact factor 2.565)
  8. Pandey M, Choudhury H, Yeun OC, Yin HM, Lynn TW, Tine CLY, Wi NS, Yen KCC, Phing CS,
    Kesharwani P, Bhattamisra SK, Gorain B. Perspectives of nanoemulsion strategies in the improvement of oral, parenteral and transdermal chemotherapy. Curr Pharm Biotechnol. 2018 Jun 5. doi: 10.2174/1389201019666180605125234. [Epub ahead of print] (Impact factor 2.459)
  9. Choudhury H, Pandey M, Chin PX, Phang YL, Cheah JY, Ooi SC, Mak KK, Pichika MR,
    Kesharwani P, Hussain Z, Gorain B. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res. 2018 Oct;8(5):1545-1563. doi: 10.1007/s13346-018-0552-2. [Epub ahead of print]
    (Impact factor 4.615)
  10. Gorain B, Choudhury H, Pandey M, Kesharwani P. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Mater Sci Eng C Mater Biol Appl. Oct 2018;91:868-880.(Impact factor 7.328)
  11. Mishra V, Thakur S, Kesharwani P, Gupta P, Vyas M. Precision medicine in cancer treatment: An update. Asian Journal of Pharmaceutics • Jan-Mar 2018 (Suppl) • 12 (1) | S9-S12.
  12. Gorain B, Choudhury H, Pandey M, Kesharwani P. Mechanistic description of natural herbs in the treatment of dementia: A systematic review. Current Psychopharmacology, Volume 7, Number 2, 2018, pp. 149-164(16) DOI: 10.2174/2211556007666180420124544
    (Impact factor 0.149)

100.  Mak KK, Pichika MR, Ling LR, Sern JCC, Yang SC, Ying TW, Yin HM, Dione MS, Hui OK, Chyi ALY, Balijepalli MK,
Kesharwani P*. Comparison of cisplatin monotherapy and cisplatin-containing combination therapy in term of survival rate in recurrent cervical cancer. Acta Scientific Pharmaceutical Sciences. 2018;2:3:22-28.


101.  Nallamolu S, Jayanti VR, Chitneni M,
Kesharwani P*. Solubility enhancement of poorly water-soluble drug aprepitant for oral delivery by self-micro emulsifying drug. Acta Scientific Pharmaceutical Sciences. 2018;2:3:2-13.


102.  Bapat RA, Joshi CP, Bapat P, Chaubal TV, Pandurangappa R, Jnanendrappa N, Gorain B, Khurana S, Kesharwani P*. The use of nanoparticles as biomaterials in dentistry. Drug Discovery Today, Volume 24, Issue 1, January 2019, Pages 85-98 Drug Discov Today. 2018. doi: 10.1016/j.drudis.2018.08.012. [Epub ahead of print]
(Impact factor 7.851)


103.  Meher JG, Dixit S, Pathan DK, Singh Y, Chandasana H, Pawar VK, Sharma M, Bhatta RS, Konwar R,
Kesharwani P, Chourasia MK. Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S344-S358. DOI: ps://doi.org/10.1080/21691401.2018.1492933
(Impact factor 5.678)


104.  Gorain B, Choudhury H, Pandey M,
Kesharwani P, Abeer MM, Tekade RK, Hussain Z. Carbon nanotube scaffolds as emerging nanoplatform for myocardial tissue regeneration: A review of recent developments and therapeutic implications. Biomedicine & Pharmacotherapy Aug 2018;104:496-508. (Impact factor 6.529)


105.  Mishra V, Kesharwani P, Jain NK. Biomedical applications and toxicological aspects of functionalized carbon nanotubes. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2018;35:4:293-330.
(Impact factor 4.889)


106.  Tambuwala MM, Kesharwani P, Shukla R, Thompson PD, McCarron PA. Caffeic acid phenethyl ester (CAPE) reverses fibrosis caused by chronic colon inflammation in murine model of colitis. Pathol Res Pract. 2018 Nov;214(11):1909-1911 (Impact Factor: 3.250).


Year 2019:


107.  Kesharwani P*, Choudhury H, Meher JG, Pandey M, Gorain B. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Progress in Materials Science, June 2019:103:484-508
(IMPACT FACTOR: 39.580).


108.  Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R,
Kesharwani P*. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discovery Today, Volume 25, Issue 1, January 2020, Pages 223-229. doi: 10.1016/j.drudis.2019.11.003. [Epub ahead of print]
(Impact factor 7.851).


109.  Choudhury H, Pandey M, Yin TH, Kaur T, Jia GW, Tan SQL, Weijie H, Yang EKS, Keat CG, Bhattamishra SK,
Kesharwani P, Md S, Molugulu N, Pichika MR, Gorain B. Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology. Mater Sci Eng C Mater Biol Appl. Aug 2019;101:596-613.
(Impact factor 7.328)


110.  Choudhury H, Gorain B, Pandey M, Kaur R,
Kesharwani P*. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm. June 2019;565:509-522
(Impact factor 5.875).


111.  Dwivedi N, Shaha J, Mishra V, Tambuwala M,
Kesharwani P*. Nanoneuromedicine for management of neurodegenerative disorder. Journal of Drug Delivery Science and Technology. Feb 2019;49:477-490
(Impact Factor: 3.981).


112.  Pandey D,
Kesharwani P*, Jain D. Entrapment of drug-sorbate complex in submicron emulsion: A potential approach to improve antimicrobial activity in bacterial corneal infection. Journal of Drug Delivery Science and Technology 2019;49:February 2019:455-462.
(Impact Factor: 3.981).


113.  Zeeshan, F., Tabbassum, M. &Kesharwani, P*. Investigation on secondary structure alterations of protein drugs as an indicator of their biological activity upon thermal exposure. Protein J. 2019 Oct;38(5):551-564. doi: 10.1007/s10930-019-09837-4.
(Impact factor 2.371)


114.  Bapat RA, Dharmadhikari S, Chaubal TV, Amin MCIM, Bapat P, Gorain B, Choudhury H, Vincent C,
Kesharwani P*. The potential of dendrimer in delivery of therapeutics for dentistry. Heliyon. Oct 2019;5(10):e02544.


115.  Tripathi PK, Gorain B, Choudhury H, Srivastava A,
Kesharwani P*. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon 4 (March 2019) e01343.
https://doi.org/10.1016/j.


116.  Bakshi HA, Mishra V, Satija S, Mehta M, Hakkim FL,
Kesharwani P, Dua K, Chellappan DK, Charbe NB, Shrivastava G, Rajeshkumar S, Aljabali AA, Al-Trad B, Pabreja K, Tambuwala MM. Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis. Inflammation. Dec 2019;42(6):2032-2036. doi: 10.1007/s10753-019-01065-3 (Impact Factor: 4.092).


117.  Choudhury H, Zakaria NFB, Tilang PAB, Tzeyung AS, Pandey M, Chatterjee B, Alhakamy NA, Bhattamishra SK,
Kesharwani P, Gorain B, Md S. Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery. Journal of Drug Delivery Science and Technology. Dec 2019;54:101301
(Impact Factor: 3.981).


Year 2020:


118.  G.S. Bhagwat, R.B. Athawale, R.P. Gude, S. Md, N.A. Alhakamy, U.A. Fahmy,
P. Kesharwani*, Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy, Front. Pharmacol. 11 (2020). https://doi.org/10.3389/fphar.2020.614290.
(Impact factor 5.810)


119.  P. Rathore, A. Mahor, S Jain, A. Haque,
P. Kesharwani*. Formulation development, in vitro and in vivo evaluation of chitosan engineered nanoparticles for ocular delivery of insulin. RSC Adv., 2020, 10, 43629-43639. DOI: 10.1039/D0RA07640F
(Impact factor 3.361)


120.  Gorain B, Choudhury H, Molugulu N, Athawale RB,
Kesharwani P*. (2020) Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global Economy. Front. Public Health 8:606129. doi: 10.3389/fpubh.2020.606129
(Impact factor 5.810)


121.  Maddiboyina, B.; Hanumanaik, M.; Nakkala, R. K.; Jhawat, V.; Rawat, P.; Alam, A.; Foudah, A. I.; Alrobaian, M. M.; Shukla, R.; Singh, S.;
Kesharwani, P*. Formulation and Evaluation of Gastro-Retentive Floating Bilayer Tablet for the Treatment of Hypertension. Heliyon 2020, 6 (11), e05459.
https://doi.org/10.1016/j.heliyon.2020.e05459.


122.  Agrawal, M.; Saraf, S.; Saraf, S.; Murty, U. S.; Kurundkar, S. B.; Roy, D.; Joshi, P.; Sable, D.; Choudhary, Y. K.;
Kesharwani, P*.; et al. In-Line Treatments and Clinical Initiatives to Fight against COVID-19 Outbreak. Respir. Med. 2020, 106192. https://doi.org/10.1016/j.rmed.2020.106192.
(Impact factor 3.095)


123.  Sood, S.; Maddiboyina, B.; Rawat, P.; Garg, A. K.; Foudah, A. I.; Alam, A.; Aldawsari, H. M.; Riadi, Y.; Singh, S.;
Kesharwani, P*. Enhancing the Solubility of Nitazoxanide with Solid Dispersions Technique: Formulation, Evaluation, and Cytotoxicity Study. J. Biomater. Sci. Polym. Ed. 2021 Mar;32(4):477-487 https://doi.org/10.1080/09205063.2020.1844506. (Impact factor 3.517)


124.  Krishna KV, Dubey SK, Singhvi G,
Kesharwani P*. MAPK Pathway: Potential role in Glioblastoma Multiforme, Interdisciplinary Neurosurgery, Volume 23, March 2021, 100901
https://doi.org/10.1016/j.inat.2020.100901.


125.  Hejmady S, Pradhan R, Alexander A, Agrawal M, Singhvi G, Gorain B, Tiwari S,
Kesharwani P*, Dubey SK. Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discovery Today, Volume 25, Issue 12, December 2020, Pages 2227-2244. https://doi.org/10.1016/j.drudis.2020.09.031
(Impact factor 7.851)


126.  Singh PK, Gorain B, Choudhury H, Singh SK, Whadwa P, Sahu SS, Gulati M,
Kesharwani P*. Macrophage targeted amphotericin B nanodelivery systems against visceral leishmaniasis, Materials Science and Engineering: B, Volume 258, August 2020, 114571
https://doi.org/10.1016/j.mseb.2020.114571.
(Impact factor 4.051)


127.  Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Gupta U,
Kesharwani P, Ravichandiran V, Kumar P, Naidu VGM, Murty US, Ajazuddin A, Alexander A. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery, J. Control. Release. 327 (2020) 235–265. https://doi.org/10.1016/j.jconrel.2020.07.044.
(Impact factor 9.776)


128.  Nallamolu S, Jayanti VR, Chitneni M, Khoon LY,
Kesharwani P*. Self-micro Emulsifying Drug Delivery System “SMEDDS” for Efficient Oral Delivery of Andrographolide, Drug Deliv. Lett. 10 (July 2019) 38–53.
https://doi.org/10.2174/2210303109666190723145209.


129.  Bapat RA, Chaubal TV, Dharmadhikari S, Abdulla AM, Bapat P, Alexander A, Dubey SK,
Kesharwani P*. Recent advances of gold nanoparticles as biomaterial in dentistry. Int J Pharm. Aug 2020;586:119596
https://doi.org/10.1016/j.ijpharm.2020.119596
(Impact factor 5.875)


130.  Singh S, Alrobaian MM, Molugulu N, Agrawal N, Numan A,
Kesharwani P*. Pyramid-shaped PEG-PCL-PEG polymeric-based model systems for site-specific drug delivery of vancomycin with enhance antibacterial efficacy. ACS Omega, May 2020, 5, 21, 11935–11945
https://doi.org/10.1021/acsomega.9b04064
(Impact factor 3.521)


131.  Gorain B, Choudhury H, Nair AB, Dubey SK, Kesharwani P*. Theranostic application of nanoemulsion in chemotherapy. Drug Discovery Today, Volume 25, Issue 7, July 2020, Pages 1174-1188 DOI: https://doi.org/10.1016/j.drudis.2020.04.013(Impact factor 7.851)


132.  Singh S, Numan A, Agrawal N, Tambuwala MW, Singh V,
Kesharwani P*. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. International Immunopharmacology June 2020;83:106417
https://doi.org/10.1016/j.intimp.2020.106417
(Impact factor 4.932)


133.  Choudhury H, Pandey M, Qing Y, Che L, Low Y, Lee CT, Cheng Marilyn TCL, Loh HS, Lim YP, Lee CF, Bhattamishra SK, Kesharwani P, Gorain B. Silver nanoparticles: Advanced and promising technology in diabetic wound therapy. Materials Science and Engineering: C 2020;112:110925
https://doi.org/10.1016/j.msec.2020.110925
(Impact factor 7.328)


134.  Gorain B, Rajeswary DC, Pandey M,
Kesharwani P, Kumbhar SA,
Choudhury H. Nose to brain delivery of nanocarriers towards attenuation of demented condition. Current Pharmaceutical Design. DOI:
https://doi.org/10.2174/1381612826666200313125613(Impact Factor: 3.116)


135. 

No items yet!

    No items yet!

    No items yet!

Your experience on this site will be improved by allowing cookies.